Article Figures & Data
Figures
- Fig. 1.
Mesothelin mRNA and protein expression in frozen tissue specimens of lung cancer patients. A, reverse transcription-PCR detection of mesothelin mRNA in frozen tissue specimens. Water, a template-free negative control; Ov, Ovcar-3 cells as a positive control; Ad, lung adenocarcinoma tissues; Sq, squamous cell carcinoma; Sm, small cell lung cancer. B, Western blot detection of mesothelin proteins in frozen tissue specimens. MSLN, mesothelin. H9 is the A431.MSLN+ (H9) stable transfected cell line used as a positive control (18).
- Fig. 2.
Summary of immunoreactivity patterns in cancer patient samples. Immunohistochemical evaluation using two different mAbs, 5B2 (A) and MB (B), shows strong and diffuse expression of mesothelin in two of four representative lung adenocarcinoma (Adeno) samples. Ca, carcinoma.
- Fig. 3.
Mesothelin mRNA and protein expression in the NCI-60 lung cancer cell lines. A, reverse transcription-PCR detection of mesothelin mRNA. Water, a template-free negative control for PCR contamination; Ovcar-3, a positive control. B, Western blot detection of mesothelin proteins. H9 is the A431.MSLN+ (H9) stable transfected cell line used as a positive control (18).
- Fig. 4.
Flow cytometric analysis of mesothelin protein expression in NCI-60 lung cancer cell lines. NCI-H322M (H322M), NCI-H522 (H522), A549, NCI-H460 (H460), and EKVX cells were probed with a mesothelin-specific mAb (solid dark line) or an irrelevant isotype mAb control (gray line). Ovcar-3 was used as a positive control.
- Fig. 5.
Inhibition of cell viability on NCI-60 lung cancer cells by immunotoxins. Cancer cells (10,000 per well) incubated with various concentrations of anti-mesothelin immunotoxins (SS1P) for 72 h. Cell viability was determined by a WST assay as described in Materials and Methods. Points, means of triplicate determinations; bars, SD. The dashed line indicates 50% inhibition of cell viability, which is halfway between the level of viability in the absence of toxin and that in the presence of 10 μg/mL of cycloheximide.
Volume 13, Issue 5
